The Product Lifecycle: - ICON plc
The Product Lifecycle: - ICON plc
The Product Lifecycle: - ICON plc
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Clinical Research<br />
Pre-clinical Phase l Phase ll Phase lll Phase lV Post Approval<br />
<strong>Product</strong> Portfolio Review<br />
Clinical Development Support<br />
Phase lV and Observational Research<br />
Scientific and Medical Communications<br />
Our experienced staff work collaboratively to support the global research and positioning<br />
needs of our clients throughout the product lifecycle, beginning with <strong>Product</strong> Portfolio Review.<br />
<strong>Product</strong> Portfolio Review<br />
<strong>ICON</strong>’s <strong>Lifecycle</strong> Sciences group can answer a range of<br />
questions that may arise during product portfolio review<br />
using a variety of approaches, including retrospective studies,<br />
economic modeling, literature review, and expert interviews:<br />
• What is the patient or caregiver burden of illness?<br />
• What is the cost of existing treatments?<br />
• What is the potential impact of a new drug on costs of<br />
treatment?<br />
• What are the current provider practice patterns for this<br />
disease?<br />
• What is the current reimbursement environment for a<br />
potential product?<br />
• What is the impact of regional and national policy on<br />
product adoption?<br />
• What economic and patient reported outcomes are likely<br />
to be needed?<br />
• What is the potential impact of alternative pricing or<br />
reimbursement plans?<br />
Challenge:<br />
Our client wanted to identify the burden of illness and<br />
the economics for a product in development for the<br />
acute conversion of Atrial fibrillation (Afib), a common<br />
but potentially serious condition.<br />
Solution:<br />
• Developed a Health Economic strategic development plan,<br />
including specific recommendations for future research to<br />
be conducted.<br />
• Conducted a health economic landscape assessment of Afib.<br />
• Completed an assessment of the feasibility of utilizing different,<br />
existing data sources to estimate the cost of treating Afib,<br />
and evaluate the reimbursement landscape surrounding the<br />
management of this condition.<br />
• Conducted an analysis of an administrative and hospital database<br />
to estimate treatment costs, length of stay, and adverse events in<br />
Afib patients treated in various inpatient and outpatient settings.<br />
• Prepared several conference presentations and a manuscript to<br />
support findings.<br />
• Developed a budget impact model and supporting content for the<br />
AMCP dossier for the product.<br />
2
Change language